Compare CSX Corporation (CSX) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Illumina, Inc. — how do they compare? CSX Corporation trades at $47.3 (market cap $87.70B), while Illumina, Inc. trades at $278.99 (market cap $39.95B). The key difference: CSX Corporation is far larger — about 2.2× Illumina, Inc.'s market cap, and CSX Corporation pays a 1.18% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Illumina, Inc. for 83 Days on average.
| CSX | ILMN | |
|---|---|---|
Market Cap | $87.70B | $39.95B |
Volume | 6,980,781 | 3,169,503 |
Sector | Industrials | Health |
52-Week High | $53.21 | $293.69 |
52-Week Low | $33.68 | $91.00 |
Typical Hold Time | 55 Days | 83 Days |
Enterprise Value | $105.66B | $41.31B |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $47.26, up 0.96% with a bullish technical signal. The stock shows strong profitability with 22.21% net margin and 24.37% ROE, though revenue declined to $14.09B in 2025. Recent Q2 2026 earnings beat expectations at $0.54 vs $0.518. Analyst consensus is bullish with 58.69% buy ratings and $51.00 price target. The company maintains stable cash flow operations and recently announced a $0.14 dividend payable September 2026.
CSX presents a favorable investment case with strong fundamentals and analyst support, though valuation metrics appear elevated. Key risks include revenue pressure and competitive threats. The upcoming Q3 2026 earnings on October 21 will be critical for confirming the positive trend. Current levels offer potential upside to consensus targets but require monitoring of operational execution.
Illumina (ILMN) trades at $278.17, up 3.89% today and near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent inclusion in the S&P 500 and positive analyst upgrades reflect growing institutional confidence. Revenue remains stable at $4.34B for 2025 with improved profitability, delivering $850M net income after previous losses.
The outlook remains positive with sequencing growth and AI initiatives driving momentum, though elevated valuation ratios and China market headwinds present risks. Analyst consensus leans bullish with 54% buy ratings, but the current price exceeds the $241 consensus target, suggesting near-term consolidation potential before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
